Page last updated: 2024-08-25

lycorine and Prostatic Neoplasms

lycorine has been researched along with Prostatic Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Huang, T; Kang, J; Li, C; Liu, X; Wang, H1
Cong, X; He, Y; Hu, M; Liu, M; Peng, S; Qin, M; Xing, Y; Yi, Z1

Other Studies

2 other study(ies) available for lycorine and Prostatic Neoplasms

ArticleYear
Construction of Fluorescein Isothiocyanate-Labeled MSNs/PEG/Lycorine/Antibody as Drug Carrier for Targeting Prostate Cancer Cells.
    Journal of nanoscience and nanotechnology, 2018, Jul-01, Volume: 18, Issue:7

    Topics: Amaryllidaceae Alkaloids; Antibodies; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Fluorescein; Humans; Isothiocyanates; Male; Nanocomposites; Nanoparticles; Phenanthridines; Prostatic Neoplasms

2018
Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer.
    Oncotarget, 2015, Jun-20, Volume: 6, Issue:17

    Topics: Amaryllidaceae Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Epidermal Growth Factor; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Phenanthridines; Prostatic Neoplasms; Signal Transduction; STAT3 Transcription Factor; Transplantation, Heterologous

2015
chemdatabank.com